Danaher Corporation $DHR Stock Bought by Focus Financial Network Inc.

Focus Financial Network Inc. grew its stake in shares of Danaher Corporation (NYSE:DHR) by 163.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 26,939 shares of the conglomerate’s stock after acquiring an additional 16,699 shares during the period. Focus Financial Network Inc.’s holdings in Danaher were worth $5,968,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Roberts Wealth Advisors LLC acquired a new position in shares of Danaher in the 3rd quarter worth $1,936,000. Enclave Advisors LLC raised its position in shares of Danaher by 104.9% during the third quarter. Enclave Advisors LLC now owns 5,102 shares of the conglomerate’s stock worth $1,130,000 after purchasing an additional 2,612 shares during the period. Salem Investment Counselors Inc. raised its position in shares of Danaher by 1,462.8% during the third quarter. Salem Investment Counselors Inc. now owns 8,939 shares of the conglomerate’s stock worth $1,980,000 after purchasing an additional 8,367 shares during the period. Keystone Financial Group Inc. purchased a new stake in shares of Danaher during the third quarter valued at $640,000. Finally, Signal Advisors Wealth LLC purchased a new stake in shares of Danaher during the third quarter valued at $1,459,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

Shares of Danaher stock opened at $223.30 on Wednesday. The stock has a market cap of $156.98 billion, a PE ratio of 39.66, a price-to-earnings-growth ratio of 2.78 and a beta of 0.76. The business has a fifty day simple moving average of $212.41 and a 200-day simple moving average of $195.13. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.77 earnings per share. On average, sell-side analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. UBS Group started coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective on the stock. TD Cowen upped their price objective on shares of Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Wells Fargo & Company decreased their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.